Хайлтын үр дүнгүүд - Heidrun Bosch‐Traberg

  • 6-н 1 - 6 үр дүнгүүдийг харуулж байна
Үр дүнг сайжруулах
  1. 1
    Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial

    Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial -н Yutaka Seino, Shizuka Kaneko, Shuichi Fukuda, Takeshi Osonoi, Toshihiko Shiraiwa, Keiji Nishijima, Heidrun Bosch‐Traberg, Kohei Kaku

    Хэвлэсэн 2015
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial

    Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial -н Katherine R. Tuttle, Stephen C. Bain, Heidrun Bosch‐Traberg, Kamlesh Khunti, Søren Rasmussen, Ekaterina Sokareva, David Z. Cherney

    Хэвлэсэн 2024
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo

    Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney fun... -н Katherine R. Tuttle, Heidrun Bosch‐Traberg, David Z.I. Cherney, Samy Hadjadj, Jack Lawson, Ofri Mosenzon, Søren Rasmussen, Stephen C. Bain

    Хэвлэсэн 2023
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial

    Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Cl... -н Melanie J. Davies, Stephen C. Bain, Stephen L. Atkin, Peter Rossing, David A. Scott, Минара Шамхаловна Шамхалова, Heidrun Bosch‐Traberg, Annika Syrén, Guillermo E. Umpierrez

    Хэвлэсэн 2015
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

    The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease -н Peter Rossing, Florian M.M. Baeres, George L. Bakris, Heidrun Bosch‐Traberg, Mette Gislum, Stephen Gough, Thomas Idorn, Jack Lawson, Kenneth W. Mahaffey, Johannes F.E. Mann, Henriette Mersebach, Vlado Perkovic, Katherine R. Tuttle, Richard Pratley

    Хэвлэсэн 2023
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

    Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial -н Johannes F.E. Mann, Peter Rossing, George L. Bakris, Nicolas Belmar, Heidrun Bosch‐Traberg, Robert S. Busch, David M. Charytan, Samy Hadjadj, Pieter Gillard, José Luis Górriz, Thomas Idorn, Linong Ji, Kenneth W. Mahaffey, Vlado Perkovic, Søren Rasmussen, Roland E. Schmieder, Richard E. Pratley, Katherine R. Tuttle

    Хэвлэсэн 2024
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: